25-Hydroxycholecalciferol receptors in human breast cancer

Murphy, LJ; Wild, Jennifer; Posen, Solomon; Stone, G. M.

doi:10.1038/bjc.1979.97

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with vitamin D compounds was shown to inhibit the development of cancer in a carcinogen-induced model in the hamster; vitamin D receptor (VDR) was detected in human cancer cells and growth arrest in vitro . 1 2 3 This paper seeks to provide an overview of studies of vitamin D in prostate cancer. However, given the ubiquitous expression of VDR as well as the vitamin D synthesizing and degrading enzymes ( e.g ., CYP 24a1, CYP27b1) in almost all human tissues, and cancers that arise from those tissues, there is every reason to believe that vitamin D signaling may play a role in the genesis, outcome, and treatment of other types of cancer.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D in prostate cancer

Trump

Aragon‐Ching

2018

Asian J Androl

View full text Add to dashboard Cite

Signaling through the vitamin D receptor has been shown to be biologically active and important in a number of preclinical studies in prostate and other cancers. Epidemiologic data also indicate that vitamin D signaling may be important in the cause and prognosis of prostate and other cancers. These data indicate that perturbation of vitamin D signaling may be a target for the prevention and treatment of prostate cancer. Large studies of vitamin D supplementation will be required to determine whether these observations can be translated into prevention strategies. This paper reviews the available data in the use of vitamin D compounds in the treatment of prostate cancer. Clinical data are limited which support the use of vitamin D compounds in the management of men with prostate cancer. However, clinical trials guided by existing preclinical data are limited.

show abstract

Section: Introductionmentioning

confidence: 99%

Vitamin D in prostate cancer

Trump

Aragon‐Ching

2018

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Critical experiments, reported in the 1970s and early 1980s, form the basis for the hypothesis that vitamin D compounds can be used to inhibit the development and progression of several types of cancer: treatment with vitamin D compounds was shown to inhibit the development of cancer in a carcinogen-induced model in the hamster the vitamin D receptor (VDR) was detected in numerous histotypes of human cancer cells treatment of cancer cells with calcitriol (1,25dihydroxycholecalciferol) in vitro was shown to cause growth arrest ( Potter et al, 1985 ; Moqattash et al, 1985 ; Freake et al, 1984 ; Sato et al, 1984 ; Kuroki et al, 1983 ; Frampton et al, 1983 ; Frankel et al, 1983 ; Mccarthy et al, 1983 ; Honma et al, 1983 ; Sato et al, 1982 ; Freake & Macintyre, 1982 ; Tanaka et al, 1982 ; Colston et al, 1982 ; Frampton et al, 1982 ; Eisman et al, 1981 ; Sher et al, 1981 ; Miyaura et al, 1981 ; Abe et al, 1981 ; Colston et al, 1981 ; Eisman et al, 1980a ; Fry et al, 1980 ; Eisman et al, 1980b ; Manolagas et al, 1980 ; Eisman et al, 1980c ; Eisman et al, 1979 ; Murphy et al, 1979 ; Rubin & Levij, 1973 ). …”

Section: Introductionmentioning

confidence: 99%

Calcitriol and cancer therapy: A missed opportunity

Trump

2018

Bone Reports

View full text Add to dashboard Cite

The vitamin D receptor is expressed in most tissues of the body – and the cancers that arise from those tissues. The vitamin D signaling pathway is active in those tissues and cancers. This is at least consistent with the hypothesis that perturbing this signaling may have a favorable effect on the genesis and growth of cancers. Epidemiologic data indicate that vitamin D signaling may be important in the initiation and outcome of a number of types of cancer. Many studies have shown that calcitriol (1,25 dihydroxycholecalciferol) and other vitamin D compounds have antiproliferative, pro-apoptotic, anti-cell migration and antiangiogenic activity in a number of preclinical studies in many different cancer types. Unfortunately, the assessment of the activity of calcitriol or other vitamin D analogues in the treatment of cancer, as single agents or in combination with other anticancer agents has been stymied by the failure to adhere to commonly accepted principles of drug development and clinical trials conduct.

show abstract

Oestrogen receptors and breast cancer: Current status

Hawkins

Roberts

Forrest

1980

Journal of British Surgery

183

View full text Add to dashboard Cite

al.: The binding of estradiol in the uterus: a mechanism for dere ression of RNA synthesis. Proc. Natl Acad. Sci. 1964; 5 H 1059-66. COCHET c., CHEDIN M. and CHAMBAZ E. M.: Characterisation of steroid-binding macromolecule in small biological samples by a rapid minigel filtration method. Analyt. Biochem. 1976; 7 6 351-7. STECGLES A. w. and KING R. J. B.: The use of protamine to study [6,7-"H] oestradiol-17s binding in rat uterus. Biochem. J. 1970; 118: 695-701. GORSKI J., TOFT D., SHYMALA G. et al.: Hormone receptors: studies on the interaction of estrogen with the uterus. Recent Prog. Hormone Res. 1967; 24: 45-80. PUCA G. A., SICA v. and NOLA E.: Identification of a high affinity nuclear acceptor site for estrogen receptor of calf uterus. Proc. Nail Acad. Sci. 1974; 71: 979-83. MEANS A. R. and HAMILTON T. H.: Early estrogen action: concomitant stimulations within two minutes of nuclear RNA synthesis and uptake of RNA precursor by the uterus. Proc. Narl Acad. Sci. 1966; 56: 1594-8. SZEGO M. and ROBERTS s.: Steroid action and interaction in uterine metabolism. Recent Progr. Hormone Res. 1953; 8: LIPPMAN M. E. and BOLAN G.: Oestrogen-responsive human breast cancer in long-term tissue culture. Nature (Lond.) 1975; 256: 592-3. ASTWOOD E. B.: A six-hour assay for the quantitative determination of estrogen. Endocrinology 1938; 2 3 O'MALLEY B. w. and SCHRADER w . J.: The receptors of steroid hormones. Scientific American 1976; 234: 32-43. KORENMAN s. G.: Radioligand binding assay of specific estrogens using a soluble uterine macromolecule. J . Clin. Endocrinol. Metabol. 1968; 28: 127-30. ERDOS T., BEST-BELPOMME M. and BESSADA R.: A rapid assay for binding estradiol to uterine receptors. Analyt. Biochem. 1970; 37 24-52, TEULINGS F. A. G., BLONK VAN DER WIJST J., PORTENGEN H. . (ed.): Estrogen Receptors in Human Breast Cancer. New York: Raven Press, 1975: 93-105. DAEHNFELDT J. L. and SCHULEIN M.: High affinity oestradiol receptors and the activity of glucose-&phosphate dehydrogenase and lactose synthetase in mammary carcinomata of postmenopausal women. Br. J. Cancer 1975; LECLERCQ G., HEUSON I. c., DEBOEL M. c. et al.: Oestrogen receptors in breast cancer: a changing concept. Br. Med. 428-30. 105-20. 31: 424-8. J . 1975; 1: 185-9.

show abstract

25-Hydroxycholecalciferol receptors in human breast cancer

Abstract: Summary.-Cytosol receptors for 25-hydroxycholecalciferol, oestradiol and progesterone were measured in human mammary carcinomas. Significant positive correlations were found between the concentrations of all three receptors.

Cited by 7 publications

References 11 publications

Vitamin D in prostate cancer

Vitamin D in prostate cancer

Calcitriol and cancer therapy: A missed opportunity

Oestrogen receptors and breast cancer: Current status

Contact Info

Product

Resources

About